Sign in
Taking peopleNo phase

Tests urine DNA as a possible replacement for bladder scopes in urothelial cancer

Studies urine DNA testing in adults suspected of urothelial cancer from blood in urine.

Key facts

Who runs it
Tampere University Hospital
Where
Chicago, United StatesSee the siteAlso in 3 other countries, 7 sites
Trial code
Registry title
Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
Status
Recruiting
People taking part
3,000 people, planned
Started
8 Jan 2024
Expected to end
31 Dec 2029
Type of study
Observational
Record updated
10 October 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who are scheduled for a cystoscopy to check for urothelial cancer. It tests whether a urine DNA test could replace some cystoscopies.

Age
18 Years to 100 Years
Sex
All sexes
Disease stage
People with suspected urothelial cancer who are scheduled for a cystoscopy; no cancer diagnosis yet.

Main reasons for not taking part

  • Earlier diagnosis of urothelial cancer (bladder cancer or upper tract urothelial carcinoma)
  • Cannot or will not give informed consent

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Willing and able to provide informed consent
  • Patient has been scheduled for cystoscopy to rule out urothelial cancer

Who cannot take part

  • Prior diagnosis of urothelial cancer (i.e. bladder cancer or upper tract urothelial carcinoma)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 100 years old?

Where in United States

Also in 3 other countries, 7 sites

  • Jesse Brown Department Of Veterans Affairs Medical CenterChicago, United StatesContact: Joel CornfieldNot yet recruiting

About the trial

What the trial wants to find out

Urothelial cancers of the bladder and upper urinary tract account for over 200,000 deaths and 600,000 diagnoses annually worldwide. The most common presenting symptom is hematuria (blood in urine), triggering a cascade of tests, including an invasive examination of the bladder using a flexible scope (cystoscopy). Millions of cystoscopies are performed every year worldwide for patients presenting with hematuria, but only 10% result in a cancer diagnosis. The UROSCOUT-1 trial is a prospective multicenter observational study that explores the potential of urine tumor DNA (utDNA) testing to replace a significant portion of cystoscopies in the diagnostic setting for hematuria or other reasons to rule out urothelial cancer. The goal is to enhance patient quality of life, reduce healthcare costs, and address increased workloads in urology centers. Sample collection will be conducted by mail, and the samples will be analyzed in a blinded manner, without knowledge of which patients are diagnosed with cancer. Random subsampling will be applied to cancer-negative patients to achieve an approximate 1:1 ratio between cancer-positive and -negative patients.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Observational Prospective Multicenter Validation Study Investigating the Possibility of Replacing Cystoscopies With High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer (UROSCOUT-1)
Plain-language title
Tests urine DNA as a possible replacement for bladder scopes in urothelial cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06310759, who can take part
Record updated
10 October 2025